However, some longitudinal studies have suggested that plasma p-Tau and measures can predict cognitive decline during the earliest AD stages, suggesting that a lower increase in p-Tau concentrations points to preclinical stages of AD. This evidence concerns the gene MAPT and Alzheimer disease.